FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasilington,	D.C.	20070

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
I = -4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is

intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

e instruction	10.																			
Name and Address of Reporting Person* Dambkowski Carl					2. Issuer Name and Ticker or Trading Symbol Apogee Therapeutics Inc. [APGE]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
					Tipogee Therapeuties, me. [m on]								Director				10% Ov			
													1				Other (s	specify		
(F	rst) (I	Middle)		3. Date of Earliest Transaction (Month/Day/Year)											,					
C/O APOGEE THERAPEUTICS, INC.							09/04/2024								office wicd	icai (JIIICCI			
SCENT S	Г., BLDG, 17, S	ГЕ. 10	2B																	
				4. If Amendment, Date of Original Filed (Month/Day/Year)								6	6. Individual or Joint/Group Filing (Check Applicable							
												Įι								
AM M	A 0)2453											Form filed by One Reporting Person							
													Form filed by More than One Reporting							
(9	tate) (Zin\												1 6130) i i					
(5	tate) (2	<u></u>																		
	Table	l - No	on-Deriva	tive \$	Secu	rities	Acc	quired	l, Dis	posed of	, or B	enefic	ially	Own	ed					
Date			Date	/Year) Execut		ition Date,		3. 4. Securities Transaction Code (Instr. 8)		Acquired (A) of (D) (Instr. 3, 4		Sand 5) Securities Beneficia Owned Fo		ties cially I Following	Form (D) or	r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 09/04/)24					5,878	D	\$47.	17.49 ⁽²⁾ 281,580		1,580	D				
Common Stock 09/04/					024			S ⁽¹⁾		787	D \$4		06(3)	280,793			D			
			(e.g., pu	ıts, ca		varra	nts,	optic	ons,	convertib	le se	curitie	s)							
	3. Transaction Date (Month/Day/Year)	Execu	Execution Date, f any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		tion D	ate Amount of Securities Underlying Derivative		nt of ties lying tive ty (Instr.	Der Sed (Ins	curity Securities Beneficia Owned Following Reported		e C s F lly [10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Natur of Indired Beneficia Ownersh (Instr. 4)		
					T															
												.								
	1	1			I		I	Date		Expiration	1	of	1			- 1		I		
	Conversion or Exercise Price of Derivative	(First) (DGEE THERAPEUTICS, I SCENT ST., BLDG. 17, S' AM MA (State) (Table Security (Instr. 3) Stock Stock 2. Conversion or Exercise Price of Date (Month/Day/Year)	(First) (Middle) OGEE THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 10 AM MA 02453 (State) (Zip) Table I - No Security (Instr. 3) Stock Conversion or Exercise Price of Date (Month/Day/Year) Price of Derivative 3. Transaction Date (Month/Day/Year) (Month/Day/Year)	(First) (Middle) OGEE THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 102B AM MA 02453 (State) (Zip) Table I - Non-Derivation (Month/Day) Stock 09/04/20 Table II - Derivation (e.g., pt. Conversion or Exercise Price of Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year)	Conversion or Exercise Price of Derivative end address of Reporting Person* OWSKi Carl (First) (Middle) (Augustian in the second of the secon	2. Issuer Na Apogee (First) (Middle) OGEE THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 102B Table I - Non-Derivative Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock 12. Transaction Date (e.g., puts, calls, v. (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Stock 2. Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year) 2. Table II - Derivative Security (e.g., puts, calls, v. (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 3. Transaction Code (Instr. 8)	2. Issuer Name at Apogee The Apogee The Apogee The Apogee The Owski Carl (First) (Middle) DGEE THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 102B Table I - Non-Derivative Securities (Month/Day/Year) Table I - Non-Derivative Securities (Month/Day/Year) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 24. Deemed Execution Date if any (Month/Day/Year) Stock 09/04/2024 Table II - Derivative Securities A (e.g., puts, calls, warra (e.g., puts, calls, warra (e.g., puts, calls, warra (A) of Derivative Security (Month/Day/Year) 2. Transaction Date (month/Day/Year) 3. Transaction Date (e.g., puts, calls, warra (e.g., puts, calls, puts, cal	2. Issuer Name and Tick Apogee Therape (First) (Middle) OGEE THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 102B AM MA 02453 (State) (Zip) Table I - Non-Derivative Securities Accurate (Month/Day/Year) Stock 09/04/2024 Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, price of Derivative Security (Month/Day/Year) 2. Transaction Date (e.g., puts, calls, warrants, price of Derivative Security (Month/Day/Year) 3. Date of Earliest Trans 09/04/2024 4. If Amendment, Date of Execution Date, if any (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, fir any (Month/Day/Year) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4	2. Issuer Name and Ticker or TApogee Therapeutics (First) (Middle) OGEE THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 102B AM MA 02453 (State) (Zip) Table I - Non-Derivative Securities Acquired Execution Date (Month/Day/Year) (Month/Day/Year) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, optic (A) or Date (Month/Day/Year) (Conversion or Exercise Price of Derivative Security Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Code (Instr. 8) 5. Number of Date (A) or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5)	2. Issuer Name and Ticker or Trading Apogee Therapeutics, Inc Code V	Code V Amount	Code Code	Address of Reporting Person Owski Carl (First) (Middle) DGEE THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 102B Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficity (Month/Day/Year) Amage: Code V	Address of Reporting Person Owski Carl (First) (Middle) DGEE THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 102B Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially (Month/Day/Year) (Month/Day/Year) 2. Issuer Name and Ticker or Trading Symbol Apogee Therapeutics, Inc. [APGE] 3. Date of Earliest Transaction (Month/Day/Year) (State) (Zip) Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Execution Date, if any (Month/Day/Year) (Month/Day/Year) Stock 09/04/2024 Stock 09/04/2024 Table II - Derivative Securities Acquired, Disposed of, or Beneficially (Instr. 3, 4 and 5) Table II - Derivative Securities Acquired, Disposed of, or Beneficially (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially (e.g., puts, calls, warrants, options, convertible Securities) 2. Table II - Derivative Securities Acquired, Disposed of, or Beneficially (e.g., puts, calls, warrants, options, convertible Securities) 3. Transaction Date (e.g., puts, calls, warrants, options, convertible Securities) 2. Conversion Obele (Instr. 1) Amount of Number of Number (Instr. 3) Amount of Number of Number of Number (Instr. 3) Amount of Number of Number of Number (Instr. 3) Amount of Number of	Address of Reporting Person' Owski Carl (First) (Middle) OGEE THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 102B AM MA 02453 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owner (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Security (Instr. 3) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 3. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction (Month/Day/Year) (Month/Day/Y	2. Issuer Name and Ticker or Trading Symbol Apoge Therapeutics, Inc. [APGE] S. Relationship of Reporting Person' Apoge Therapeutics, Inc. [APGE] S. Relationship of Reporting Person' Chieck all applicable) Director Officer (give title below) Chief Med	2. Issuer Name and Ticker or Trading Symbol Apoge Therapeutics, Inc. [APGE]	Address of Reporting Person's Owski Carl (First) (Middle) (Size THERAPEUTICS, INC. SCENT ST., BLDG. 17, STE. 102B AM MA 02453 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Stock 09/04/2024 3. Date of Earliest Transaction (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3) 2. Issuer Name and Ticker or Trading Symbol Apoge Therapeutics, Inc. (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Security (Instr. 3) 3. Date of Earliest Transaction (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Security (Instr. 3) 3. Date of Farliest Transaction (Month/Day/Year) (Mo		

Explanation of Responses:

- 1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.
- 2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$46.79 to \$47.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range
- 3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$47.80 to \$48.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range

/s/ Matthew Batters, as attorney-in-fact for Carl

09/06/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.